Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00655655
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:15.748333+00:00
Published At
2024-08-21T00:00:00+00:00
Record Updated At
2024-08-21
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Gastrinoma", "Glucagonoma", "Insulinoma", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Pheochromocytoma", "Pancreatic Polypeptide Tumor", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Melanoma", "Recurrent Neuroendocrine Carcinoma of the Skin", "Recurrent Non-small Cell Lung Cancer", "Recurrent Pheochromocytoma", "Recurrent Renal Cell Cancer", "Somatostatinoma", "Stage III Neuroendocrine Carcinoma of the Skin", "Stage IV Melanoma", "Stage IV Non-small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Thyroid Gland Medullary Carcinoma", "Unspecified Adult Solid Tumor, Protocol Specific"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-08-21"
protocolSection.identificationModule.nctId
"NCT00655655"
protocolSection.identificationModule.officialTitle
"A Phase I Trial of the mTOR Inhibitor RAD001 in Combination With VEGF Receptor Tyrosine Kinase Inhibitor PTK787/ZK 222584 in Patients With Advanced Solid Tumors"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Gastrinoma (protocolSection.conditionsModule.conditions)
  • Glucagonoma (protocolSection.conditionsModule.conditions)
  • Insulinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Gastrointestinal Carcinoid Tumor (protocolSection.conditionsModule.conditions)
  • Metastatic Pheochromocytoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Polypeptide Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Gastrointestinal Carcinoid Tumor (protocolSection.conditionsModule.conditions)
  • Recurrent Islet Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Melanoma (protocolSection.conditionsModule.conditions)
  • Recurrent Neuroendocrine Carcinoma of the Skin (protocolSection.conditionsModule.conditions)
  • Recurrent Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Pheochromocytoma (protocolSection.conditionsModule.conditions)
  • Recurrent Renal Cell Cancer (protocolSection.conditionsModule.conditions)
  • Somatostatinoma (protocolSection.conditionsModule.conditions)
  • Stage III Neuroendocrine Carcinoma of the Skin (protocolSection.conditionsModule.conditions)
  • Stage IV Melanoma (protocolSection.conditionsModule.conditions)
  • Stage IV Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Renal Cell Cancer (protocolSection.conditionsModule.conditions)
  • Thyroid Gland Medullary Carcinoma (protocolSection.conditionsModule.conditions)
  • Unspecified Adult Solid Tumor, Protocol Specific (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.